How Mirum’s Profit Turnaround and Raised Guidance Will Impact Mirum Pharmaceuticals (MIRM) Investors

• Mirum Pharmaceuticals recently reported strong third quarter results, posting US$133.01 million in revenue and moving from a net loss to a net profit year-over-year.
• The company also raised its full-year 2025 revenue guidance, now expecting to finish at the upper end of its previous range, signaling improving business performance and management confidence.
• We'll examine how Mirum’s raised revenue guidance and profitability turnaround influence its investment narrative moving forward.

The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.

Mirum Pharmaceuticals Investment Narrative Recap

To own Mirum Pharmaceuticals stock, investors generally need confidence in the company's ability to drive robust, sustainable revenue growth through expanding its rare disease therapies and pipeline diversification. The recent move to profitability and raised 2025 revenue guidance strengthens the immediate investment case, especially for those focused on commercial execution, but it does not materially alter the primary short-term catalyst, expanding Livmarli’s patient base, or reduce the biggest risk of dependence on a single product in markets with uncertain reimbursement dynamics.

Of all recent announcements, the Q3 2025 results are most directly relevant here, with Mirum reporting US$133.01 million in quarterly revenue and achieving net profitability. This performance aligns with the raised guidance and provides tangible evidence of operating leverage, helping the company build momentum as it seeks to expand in international markets and broaden Livmarli’s reach, which are key to future growth beyond the current franchise.

However, it remains critical for investors to be mindful of how heavily Mirum relies on Livmarli for revenue, as reimbursement or competitive pressures could...

Read the full narrative on Mirum Pharmaceuticals (it's free!)

Mirum Pharmaceuticals' outlook anticipates $794.3 million in revenue and $102.1 million in earnings by 2028. This is based on a forecasted annual revenue growth rate of 22.8% and an increase in earnings of $160.7 million from the current earnings of -$58.6 million.

Uncover how Mirum Pharmaceuticals' forecasts yield a $83.55 fair value, a 18% upside to its current price.

Exploring Other Perspectives

Community members at Simply Wall St assigned Mirum a pre-news fair value from as low as US$34.86 to as high as US$213.74 across four perspectives. With competition and reimbursement risk still central, these contrasting forecasts highlight just how much opinions can differ, your own view could be just as different.

Explore 4 other fair value estimates on Mirum Pharmaceuticals - why the stock might be worth over 3x more than the current price!

Build Your Own Mirum Pharmaceuticals Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Mirum Pharmaceuticals research is our analysis highlighting 3 key rewards that could impact your investment decision.
• Our free Mirum Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Mirum Pharmaceuticals' overall financial health at a glance.

Interested In Other Possibilities?

Our top stock finds are flying under the radar-for now. Get in early:

• This technology could replace computers: discover 28 stocks that are working to make quantum computing a reality.
• Trump has pledged to "unleash" American oil and gas and these 22 US stocks have developments that are poised to benefit.
• AI is about to change healthcare. These 33 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com